Skip to main content
. 2020 Apr 28;10:603. doi: 10.3389/fonc.2020.00603

Table 3.

Efficacy of primary targeted therapy in patients with BRAF V600E mutation.

Vemurafenib Dabrafenib Dabrafenib + Trametinib
First-line 9 2 5
Further-line 4 4 4
Evaluable for response analysis 13 5 9
DCR 12/13, 92.3% 5/5, 100.0% 9/9, 100.0%
PFS, months (95% CI) 7.8 (3.9, 11.7) 5.8 (0.2, 11.4) 6.0 (5.0, 7.0)

DCR, disease control rate; PFS, progression-free survival.